PDCD1 and non-small cell lung carcinoma: Another major advancement is immunotherapy [6], notably the use of PD-1 and CTLA-4 immune checkpoint inhibitors (ICIs), which has been transformative since 2013, altering the treatment landscape not just for NSCLC, but also for small cell lung carcinoma [7,8].